Feasibility and safety of ALVAC-HIV vCP1521 vaccine in HIV-exposed infants in uganda: Results from the first HIV vaccine trial in infants in Africa

Journal of Acquired Immune Deficiency Syndromes

Volumn 63, Issue 1, 2013, Pages 1-8

  Kintu, Kenneth ^a   Andrew, Philip ^b   Musoke, Philippa ^a   Richardson, Paul ^c   Asiimwe Kateera, Brenda ^a   Nakyanzi, Teopista ^a   Wang, Lei ^d   Fowler, Mary Glenn ^c   Emel, Lynda ^d   Ou, San San ^d   Baglyos, Lynn ^e   Gurunathan, Sanjay ^e   Zwerski, Sheryl ^f   Jackson, Jay Brooks ^c   Guay, Laura ^g  

^a MAKERERE UNIVERSITY   (Uganda)

^b FAMILY HEALTH INTERNATIONAL   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Fred Hutchinson Cancer Research Center   (United States)

^e SANOFI PASTEUR   (France)

^f NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^g GEORGE WASHINGTON UNIVERSITY   (United States)

Author keywords

Africa; ALVAC; breast milk transmission; HIV vaccine; infants

Indexed keywords

ALVAC HIV VCP 1521; HAEMOPHILUS VACCINE; HEPATITIS B VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEVIRAPINE; PLACEBO; POLIOMYELITIS VACCINE; UNCLASSIFIED DRUG; VIRUS DNA; ZIDOVUDINE;

ADULT; ARTICLE; CONTROLLED STUDY; DIPHTHERIA; DOUBLE BLIND PROCEDURE; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GASTROENTERITIS; HAEMOPHILUS INFECTION; HAEMOPHILUS INFLUENZAE TYPE B; HEPATITIS B; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOGENICITY; INFANT; MAJOR CLINICAL STUDY; MEASLES; PNEUMONIA; POLIOMYELITIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; UGANDA; VACCINATION;

ADOLESCENT; ADULT; AIDS VACCINES; BREAST FEEDING; CHILD, PRESCHOOL; DOUBLE-BLIND METHOD; FEMALE; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; HUMANS; INFANT; INFANT, NEWBORN; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; MILK, HUMAN; TREATMENT OUTCOME; UGANDA; VACCINATION; YOUNG ADULT;

EID: 84876280934     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31827f1c2d     Document Type: Article

References (32)

1. UNAIDS. UNAIDS Report on the Global AIDS Epidemic 2012. Geneva, Switzerland: United Nations Programme on HIV/AIDS; 2012; 42.
2. Kourtis AP, Jamieson DJ, de Vincenzi I, et al. Prevention of human immunodeficiency virus-1 transmission to the infant through breastfeeding: new developments. Am J Obstet Gynecol. 2007;197(suppl 3):S113-S122.
3. Coutsoudis A, Dabis F, Fawzi W, et al. Late postnatal transmission of HIV-1 in breast-fed children: an individual patient data meta-analysis. J Infect Dis. 2004;189:2154-2166.
4. WHO Collaborative Study Team on the Role of Breastfeeding on the Prevention of Infant Mortality. Effect of breastfeeding on infant and child mortality due to infectious diseases in less developed countries: a pooled analysis. Lancet. 2000;355:451-455.
5. Smith MM, Kuhn L. Exclusive breast-feeding: does it have the potential to reduce breast-feeding transmission of HIV-1? Nutr Rev. 2000;58: 333-340.
6. Coovadia HM, Coutsoudis A. Problems and advances in reducing transmission of HIV-1 through breast-feeding in developing countries. AIDSci. 2001;1. Available at: http://aidscience.org/Articles/aidscience004.asp. Accessed March 8, 2013.
7. Kumwenda NI, Hoover DR, Mofenson LM, et al. Extended antiretroviral prophylaxis to reduce breast-milk HIV-1 transmission. N Engl J Med. 2008;359:119-129.
8. Bedri A, Gudetta B, Isehak A, et al. Extended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda: an analysis of three randomised controlled trials. Lancet. 2008;372:300-313.
9. Shapiro RL, Hughes MD, Ogwu A, et al. Antiretroviral regimens in pregnancy and breast-feeding in Botswana. N Engl J Med. 2010;362: 2282-2294.
10. Chasela CS, Hudgens MG, Jamieson DJ, et al. Maternal or infant anti-retroviral drugs to reduce HIV-1 transmission. N Engl J Med. 2010;362: 2271-2281.
11. Thomas TK, Masaba R, Borkowf CB, et al. Triple-antiretroviral prophylaxis to prevent mother-to-child HIV transmission through breastfeeding- the Kisumu Breastfeeding Study, Kenya: a clinical trial. PLoS Med. 2011; 8:e1001015.
12. Kesho Bora Study Group. I. Triple antiretroviral compared with zidovu-dine and single-dose nevirapine prophylaxis during pregnancy and breastfeeding for prevention of mother-to-child transmission of HIV-1 (Kesho Bora study): a randomised controlled trial. Lancet Infect Dis. 2011;11:171-180.
13. WHO. Rapid Advice: Revised WHO Principles and Recommendations on Infant Feeding in the Context of HIV-November 2009. WHO Library Cataloguing-in- Publication Data. Geneva, Switzerland: WHO; 2009.
14. Guay L. Decreasing HIV transmission through breastfeeding: moving from evidence to practice. J Acquir Immune Defic Syndr. 2011;57:258-260.
15. Mofenson LM. Prevention of mother-to-child HIV-1 transmission-why we still need a preventive HIV immunization strategy. J Acquir Immune Defic Syndr. 2011;58:359-362.
16. Johnson DC, McFarland EJ, Muresan P, et al. Safety and immunogenic-ity of an HIV-1 recombinant canarypox vaccine in newborns and infants of HIV-1-infected women. J Infect Dis. 2005;192:2129-2133.
17. Thongcharoen P, Suriyanon V, Paris RM, et al. A phase 1/2 comparative vaccine trial of the safety and immunogenicity of a CRF01-AE (subtype E) candidate vaccine: ALVAC-HIV (vCP1521) prime with oligomeric gp160 (92TH023/LAI-DID) or bivalent gp120 (CM235/SF2) boost. J Acquir Immune Defic Syndr. 2007;46:48-55.
18. Nitayaphan S, Pitisuttithum P, Karnasuta C, et al. Safety and immuno-genicity of an HIV subtype B and E prime-boost vaccine combination in HIV-negative Thai adults. J Infect Dis. 2004;190:702-706.
19. Cao H, Kaleebu P, Hom D, et al. Immunogenicity of a recombinant human immunodeficiency virus (HIV)-canarypox vaccine in HIV-seronegative Ugandan volunteers: results of the HIV Network for Prevention Trials 007 Vaccine Study. J Infect Dis. 2003;187:887-895.
20. Gupta K, Hudgens M, Corey L, et al. Safety and immunogenicity of a high-titered canarypox vaccine in combination with rgp120 in a diverse population of HIV-1-uninfected adults: AIDS Vaccine Evaluation Group Protocol 022A. J Acquir Immune Defic Syndr. 2002;29: 254-261.
21. Salmon-Ceron D, Excler JL, Finkielsztejn L, et al. Safety and immuno-genicity of a live recombinant canarypox virus expressing HIV type 1 gp120 MN MN tm/gag/protease LAI (ALVAC-HIV, vCP205) followed by a p24E-V3 MN synthetic peptide (CLTB-36) administered in healthy volunteers at low risk for HIV infection. AGIS Group and L'Agence Nationale de Recherches sur Le Sida. AIDS Res Hum Retroviruses. 1999;15:633-645.
22. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med. 2009;361:2209-2220.
23. McFarland EJ, Johnson DC, Muresan P, et al. HIV-1 vaccine induced immune responses in newborns of HIV-1 infected mothers. AIDS. 2006; 20:1481-1489.
24. McFarland EJ, Borkowsky W, Fenton T, et al. Human immunodeficiency virus type 1 (HIV-1) gp120-specific antibodies in neonates receiving an HIV-1 recombinant gp120 vaccine. J Infect Dis. 2001;184:1331-1335.
25. Cunningham CK, Wara DW, Kang M, et al. Safety of 2 recombinant human immunodeficiency virus type 1 (HIV-1) envelope vaccines in neonates born to HIV-1-infected women. Clin Infect Dis. 2001;32: 801-807.
26. HPTN. Supplemental Toxicity Table for Grading Reactogenicity Occurring Within Seven Days of Study Vaccination. Baltimore, MD: HPTN 027 protocol team; 2004.
27. DAIDS. Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events. December 2004. Bethesda, MD: National Institutes of Health; 2004; 1.
28. Cunningham CK, McFarland E. Vaccines for prevention of mother-to-child transmission of HIV. Curr Opin HIV AIDS. 2008;3:151-154.
29. Lubega IR, Fowler MG, Musoke PM, et al. Considerations in using US-based laboratory toxicity tables to evaluate laboratory toxicities among healthy Malawian and Ugandan infants. J Acquir Immune Defic Syndr. 2010;55:58-64.
30. Coovadia HM, Brown ER, Fowler MG, et al. Efficacy and safety of an extended nevirapine regimen in infant children of breastfeeding mothers with HIV-1 infection for prevention of postnatal HIV-1 transmission (HPTN 046): a randomised, double-blind, placebo-controlled trial. Lancet. 2012;379:221-228.
31. Ciaranello AL, Perez F, Keatinge J, et al. What will it take to eliminate pediatric HIV? Reaching WHO target rates of mother-to-child HIV transmission in Zimbabwe: a model-based analysis. PLoS Med. 2012;9: e1001156.
32. Mirkuzie AH, Hinderaker SG, Sisay MM, et al. Current status of medication adherence and infant follow up in the prevention of mother to child HIV transmission programme in Addis Ababa: a cohort study. J Int AIDS Soc. 2011;14:50.